AUS
NZ
UK
CA
USA
IND
Osteopore Limited (ASX:OSX) has successfully concluded a research program funded by the Chilean government, focused on developing a 3D-printed bone implant designed to enhance regenerative healing. This research marks a significant milestone for the company, which is now preparing to advance to clinical trials in the latter half of 2025. Osteopore views this progression as a key step in strengthening its presence in the Latin American market.
The study, conducted in collaboration with researchers from the University of Chile—ranked as the 400th top university globally—has yielded promising pre-clinical and pre-verification data. The project, initially supported with a grant of US$360,000, has demonstrated the implants' cytocompatibility, meaning they did not harm any cells, a crucial factor for successful bone regeneration.
In addition to validating the initial results, Osteopore’s biotech team is exploring various materials to optimize the implants and accelerate the body’s natural healing processes following bone trauma. The successful completion of this research program provides a solid foundation for the forthcoming clinical studies, underscoring Osteopore’s commitment to advancing bone implant technology.
Osteopore CEO Dr. Yujing Lim expressed optimism about the results, stating, "Although we are still at an early stage, we are highly encouraged by the outcomes. We look forward to the continued success of our research and clinical teams as we move into the next phase of evaluation."
